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AbStr ACt
An HPLC method for simultaneous determination of arenari-
oside (1), verbascoside (2), 6-hydroxyluteolin (3), 6-hydroxy-
luteolin-7-O-glycoside (4), and nodifloretin (5) from Lippia 
nodiflora in rat plasma was developed and validated. The opti-
mal chromatographic separation was achieved with a gradient 
mobile phase comprising 0.1 % aqueous acetic acid and ace-
tonitrile. The limit of detection was 78.1 ng/mL for 3 and 
39.1 ng/mL for the other compounds (signal-to-noise ratio = 3), 
whereas the limit of quantification was 312.5 ng/mL for 3 and 
156.3 ng/mL for the other compounds (signal-to-noise ra-
tio = 12). The recovery values of compounds 1–5 ranged from 
89.37–100.92 %. Their accuracy values were between 96.48 
and 105.81 %, while their corresponding precision values were 
in the range of 0.75–9.06 % for both intraday and inter-day 
analysis. The method was then applied in the first pharmacoki-
netic study of 1–5. Following intravenous administration, 1–5 
were eliminated slowly from the body with a mean clearance 
value of 0.11, 0.13, 0.30, 0.09, and 0.23 L/kg h, respectively. 
Meanwhile, their peak plasma concentration upon oral admin-
istration was 8.97, 1.07, 1.06, 0.65, and 0.38 µg/mL, respec-
tively. Compound 3 (5.97 %) exhibited the highest absolute oral 
bioavailability value, followed by 1 (5.22 %), 4 (3.13 %), 2 
(2.10 %), and 5 (0.93 %).
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AbbreViAtionS
AUC  area under the curve (AUC)
CV coefficient of variation
LOD limit of detection
LOQ limit of quantification
PPC peak plasma concentration
r2 coefficient of determination
SEM standard error of the mean
Introduction
Lippia nodiflora (L.) Michx., also known as Phyla nodiflora (L.) Greene 
[1, 2], is a fast-growing creeping perennial medicinal herb belong-
ing to the Verbenaceae family [3]. It is commonly known as Frog 
Fruit and has been traditionally used for the treatment of knee joint 
pain, lithiasis, diuresis, urinary disorders, and swelling [1–5]. The 
plant is rich in flavonoids [6–9], phenols [10], triterpenoids, and 
steroids [11, 12]. Pharmacological studies have shown that the 
plant possesses a broad array of biological properties, including 
anti-urolithiasis [13], antihypertensive [14], antioxidant [15], an-
titumor [16], and anti-inflammatory [17] activity. In addition, our 
previous study indicated that phenyethanoid glycosides and flavo-
noids of L. nodiflora were promising xanthine oxidase inhibitors 
[18]. Two phenylethanoid glycosides, namely, arenarioside (1) and 
verbascoside (2), together with three flavonoids, namely, 6-hydrox-
yluteolin (3), 6-hydroxyluteolin-7-O-glycoside (4), and nodiflore-
tin (5), isolated from L. nodiflora were shown to have an antihyper-
uricemic effect in potassium oxonate- and hypoxanthine-induced 
hyperuricemic rats, with 3 being the most active [19].
Due to the promising uric acid-lowering benefit of the phenyleth-
anoid glycosides and flavonoids reported previously [18, 19], the 
characterization of their bioavailability and pharmacokinetic prop-
erties is important for their further development into phytophar-
maceuticals. Hitherto, there is no report on the pharmacokinetic 
data of those antihyperuricemic constituents, except verbascoside. 
In addition, no analytical method has been developed for the si-
multaneous determination of the bioavailability and pharmacoki-
netics of bioactive compounds 1–5 in rats. The only study found 
was on the pharmacokinetic of acteoside, also known as verbasco-
side, from Plantago asiatica or Cistanche deserticola using liquid 
chromatography-mass spectrometry [20], liquid chromatography-
tandem mass spectrometry [21, 22], or liquid chromatography with 
amperometric detection [23]. Previously, we developed, validated, 
and applied an HPLC method for the phytochemical analysis of the 
antihyperuricemic constituents 1–5 in the plant samples [24]. In 
the present study, we aimed at the development of a simple and 
reliable HPLC method with a UV detection method for the simulta-
neous determination and quantification of the antihyperuricemic 
constituents 1–5 in rat plasma and to apply the method in the phar-
macokinetic study of those bioactive compounds in rats after oral 
and intravenous administration.
Results and Discussion
In the present study, a simple and reliable HPLC method was devel-
oped and validated. It uses UV detection and gradient elution with 
a mobile phase consisting of 0.1 % aqueous acetic acid (solvent A) 
and acetonitrile (solvent B) for the simultaneous determination and 
quantification of the five antihyperuricemic constituents in rat plas-
ma with a total run time of approximately 38 min (▶Fig. 1b). Sol-
vent A was chosen as it minimized the peak tailing effect related to 
the dissociation of the hydroxyl group of flavonoids compared to 
the acid-free solvent. Acid-containing mobile phases are often used 
for flavonoid separation [25–29]. Since phenylethanoid glycosides 
and flavonoids exhibited two different sets of UV maxima at 218 
and 332 nm, and 282 and 346 nm, respectively, a wavelength of 
340 nm producing a high absorbance for both phenylethanoid gly-
cosides and flavonoids was selected for the HPLC-UV analysis.
The calibration curves for the bioactive compounds in rat plasma 
were linear over the concentration range investigated with a mean 
slope ( ± standard error of mean) of 152.00 ± 3.75, 233.38 ± 1.25, 
540.33 ± 3.53, 627.10 ± 5.05, and 267.93 ± 5.31 for 1, 2, 3, 4, and 5, 
respectively. In addition, the coefficient of determination for the cal-
ibration curve of all five compounds was equal to or greater than 
0.9996 (▶table 1). The LOD value was 78.1 ng/mL for 3 and 39.1 ng/
mL for the rest of the compounds at a signal-to-noise ratio of 3. On 
the other hand, the LOQ value for 3 was 312.5 ng/mL, whilst for the 
rest of the compounds, it was 156.3 ng/mL at a signal-to-noise ratio 
of 12. The recovery of bioactive compounds 1–5 ranged from 
89.37–100.92 % (▶table 2), implying that deproteinization of the 
plasma with methanol did not result in any substantial loss of the 
chemical constituents. The accuracy values were between 97.95 
and 105.81 % for intraday analysis and between 96.48 and 101.13 % 
for inter-day analysis. Meanwhile, the corresponding precision val-
ues were ranged from 1.15–9.06 % for intraday analysis and ranged 
from 0.75–7.71 % for inter-day analysis. Both accuracy and preci-
sion values indicated that the developed method was reliable and 
reproducible for the simultaneous determination of the five bioac-
tive chemical constituents in rat plasma.
The developed and validated HPLC method was then success-
fully applied to simultaneously determine and quantify the 5 anti-
hyperuricemic constituents in the plasma of rats. Rats were admin-
istered, either orally (20 mg/kg each of 1–5) or intravenously (2 mg/
kg each of 1–5), a mixture of 1–5, consisting of 1, 2, 3, 4, and 5 in 
a ratio of 1:1:1:1:1. The bioactive phenylethanoid glycosides and 
flavonoids were unambiguously identified as 1–5 in the rat plasma 
upon comparison of the retention times with those of their respec-
tive standards, as shown in the ▶Fig. 1. The chromatogram of blank 
rat plasma is shown in ▶Fig. 1a–c shows the chromatogram of rat 
plasma spiked with bioactive compounds 1–5 at a concentration 
of 5 µg/mL each, whereas ▶Fig. 1d shows the chromatogram of 
rat plasma 1 h after intravenous administration of the mixture of 
1–5 (2 mg/kg each of 1–5).
(▶Fig. 2a, b) illustrates the mean plasma concentration-time 
profiles of phenylethanoid glycosides and flavonoids after intrave-
nous administration of the mixture of 1–5. Following intravenous 
administration, compounds 1–5 showed a gradual decline in the 
plasma concentration starting from the highest concentration at 
0 h. Interestingly, the concentrations of phenylethanoid glycosides 
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found in the rat plasma after intravenous administration was high-
er than those of the flavonoids, with 1 exhibiting the highest PPC 
value of 11.07 ± 0.93 µg/mL, while 2 showed the second highest 
PPC value of 8.75 ± 1.10 µg/mL, followed by 4, 5, and 3 with their 
corresponding PPC values of 8.12 ± 0.45, 5.89 ± 0.67, and 
4.13 ± 0.57 µg/mL, respectively.
(▶Fig. 3a, b) illustrates the mean plasma concentration-time 
profiles of phenylethanoid glycosides and flavonoids after oral ad-
ministration of the mixture of 1–5. Following oral administration, 
all five compounds showed a rapid rise, and reached the maximal 
concentration in the rat plasma with a Tmax ranging from 0.5–
0.67 h, indicating that they were rapidly absorbed and entered the 
blood circulation system. This finding was consistent with an ear-
lier study where a phenylethanoid glycoside, acteoside, was shown 
to reach its maximal concentration in the rat plasma (0.1 µg/mL) 
within the first 30 min after oral administration [21]. It is important 
to note that 1 showed a distinctively higher concentration in the 
rat plasma than the rest of the compounds after oral administra-
tion, with a PPC value of 8.46 ± 0.62 µg/mL, whereas compound 5 
showed the lowest concentration in the rat plasma after oral ad-
ministration with a PPC value of 0.38 ± 0.01 µg/mL. The oral admin-
istration profile pattern displayed by 2 was very similar to that dis-
played by 3, as indicated by their close mean maximum plasma 
concentration values.
▶table 3 summarizes the pharmacokinetic parameters of the 
bioactive compounds 1–5 in rat plasma after intravenous or oral 
administration of the mixture of 1–5, comprising 2 mg/kg each of 
1–5 or 20 mg/kg each of 1–5, respectively. Following intravenous 
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▶Fig. 1 HPLC chromatogram from the analysis of arenarioside (1), verbascoside (2), 6-hydroxyluteolin (3), 6-hydroxyluteolin-7-O-glycoside (4), 
and nodifloretin (5). a Blank rat plasma. b Mixed standards (10 µg/mL each of 1–5) isolated from L. nodiflora. c Rat plasma spiked with 1–5 (5 µg/mL 
each). d Rat plasma 1 h after intravenous administration of the mixture of 1–5 (2 mg/kg each of 1–5).
▶table 1 Regression equations, correlation coefficients, linear ranges, and limits of detection and quantification of the antihyperuricemic constituents  
(1–5) of L. nodiflora.
Compound regression equation r2 Linear range (ng/mL) LoD (ng/mL) LoQ (ng/mL)
Arenarioside y = 152.00x − 20.39 0.9999 156.3–20000 39.1 156.3
Verbascoside y = 233.38x − 58.81 0.9997 156.3–20000 39.1 156.3
6-Hydroxyluteolin y = 540.33x − 371.64 0.9996 312.5–20000 78.1 312.5
6-Hydroxyluteolin-7-O-glycoside y = 627.10x − 130.44 0.9996 156.3–20000 39.1 156.3
Nodifloretin y = 267.93x + 59.24 0.9996 156.3–20000 39.1 156.3
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administration, 3 exhibited the highest Vd value, implying that a 
greater amount of 3 was distributed into the tissue compartment 
compared to the other compounds. Remarkably, 4 exhibited the 
lowest mean clearance value, indicating that it has been cleared 
from the body slower than the other compounds. With regards to 
this, 4 had the longest corresponding half-life and the largest AUC 
value, suggesting that the tissue distributed compound 4 was re-
tained in tissue compartment and eliminated slowly, despite its 
relatively small volume of distribution value. Thus, while 1, 2, 3, 
and 5 showed a gradual decline to 0 at 24 h, 4 did not decline to 0 
and still could be detected even at 24 h after both oral and intrave-
nous administration.
Following oral administration, 1 showed the highest mean Cmax 
and AUC values, despite having the largest molecular size com-
pared to the other compounds. In contrast, 5 exhibited the lowest 
mean Cmax and AUC values, suggesting that its absorption after oral 
administration was incomplete. In general, the plasma levels of all 
5 compounds given orally were much lower than those of the in-
travenous administration, even though their oral doses were 10 
times higher than their intravenous doses, indicating that their oral 
bioavailability was low and incomplete. The low oral bioavailability 
might be due to the first-pass metabolism reducing the concentra-
tion of the compound before it reaches the systemic circulation 
[30]. Nevertheless, it is interesting to note that the most potent 
▶table 2 Recovery and intraday and inter-day precision and accuracy values of the bioactive compounds (1–5) of L. nodiflora.
Concentration (ng/mL) recovery (n = 3) intraday (n = 6) inter-day (n = 6)
Mean ( %) Mean 
(CV,  %)
Accuracy ( % of 
true value)
Precision 
(CV,  %)
Accuracy ( % of 
true value)
Precision 
(CV,  %)
Arenarioside 
156.3 89.37 7.43 99.77 8.09 99.68 4.66
625 92.53 3.50 100.82 4.98 98.58 6.67
2 500 93.88 3.61 99.14 4.26 96.48 4.06
5 000 96.27 5.24 101.79 2.08 99.42 3.92
10 000 95.19 4.20 105.81 3.32 101.13 2.48
20 000 96.27 4.81 99.45 2.35 100.20 2.22
Verbascoside
156.3 91.11 4.30 99.55 9.06 100.81 6.69
625 94.67 7.88 101.53 3.39 97.15 7.71
2 500 94.56 3.72 99.06 1.89 100.10 3.68
5 000 92.83 6.61 99.14 2.18 98.99 5.81
10 000 93.94 3.85 99.93 4.66 99.95 1.68
20 000 96.81 2.82 99.36 1.76 99.36 1.94
6-Hydroxyluteolin
312.5 97.33 6.57 98.95 5.10 98.96 4.84
625 91.79 6.42 100.73 5.08 99.64 5.93
2 500 90.57 4.78 100.93 1.53 99.71 1.47
5 000 92.66 6.14 98.53 3.86 100.27 5.71
10 000 90.00 2.67 100.91 2.71 99.57 2.70
20 000 92.73 3.85 99.44 3.70 99.99 2.50
6-Hydroxyluteolin-7-O-glycoside
156.3 97.47 1.43 99.91 2.15 99.21 2.55
625 100.92 4.55 99.43 3.81 100.53 5.48
2 500 96.66 2.24 102.27 2.06 100.70 2.70
5 000 92.06 3.14 100.30 1.78 99.30 1.84
10 000 95.41 1.11 98.94 1.37 99.11 1.42
20 000 97.26 2.13 100.27 1.15 99.67 0.75
Nodifloretin 
156.3 94.38 3.11 99.82 4.10 99.75 4.15
625 93.99 5.51 100.44 4.71 100.84 4.96
2 500 91.70 2.85 101.18 4.40 99.48 3.76
5 000 94.02 2.90 103.54 1.66 99.35 5.89
10 000 93.54 6.62 97.95 5.05 99.95 2.29
20 000 92.58 3.44 102.63 3.07 99.12 1.70
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antihyperuricemic constituent 3 has the highest estimated abso-
lute oral bioavailability value of 5.97 %, followed by 1, 4, 2, and 5, 
with estimated absolute oral bioavailability values of 5.22, 3.13, 
2.10, and 0.93 %, respectively.
In conclusion, the pharmacokinetic study unveiled that the oral 
bioavailability of the bioactive compounds of L. nodiflora was low 
and need to be improved, thus, further study for the development 
of phenylethanoid glycoside and flavonoid formulations to enhance 
their oral bioavailability is warranted.
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▶Fig. 3 Mean plasma concentration-time profiles of a phenylethanoid glycosides (1 and 2) and b flavonoids (3–5) after oral administration of the 
mixture of 1–5 (20 mg/kg each of 1–5); mean ± SEM, n = 6.
▶table 3 Pharmacokinetic parameters of the antihyperuricemic constituents (1–5) in rat plasma after intravenous (2 mg/kg of each compound) or oral 
(20 mg/kg of each compound) administration of the mixture of 1–5.
Parameters 1 2 3 4 5
Intravenous administration
AUC0-∞ (µg h/mL) 18.69 ± 0.79 16.72 ± 1.67 6.98 ± 0.70 22.80 ± 0.59 9.52 ± 1.30
Ke (h − 1) 0.76 ± 0.01 0.64 ± 0.04 0.45 ± 0.05 0.15 ± 0.01 1.35 ± 0.08
t1/2 (h) 0.92 ± 0.01 1.11 ± 0.08 1.65 ± 0.24 4.75 ± 0.10 0.53 ± 0.03
Vd (L/kg) 0.14 ± 0.01 0.21 ± 0.03 0.76 ± 0.18 0.60 ± 0.03 0.17 ± 0.02
CL (L/kg h) 0.11 ± 0.01 0.13 ± 0.01 0.30 ± 0.03 0.09 ± 0.01 0.23 ± 0.03
Oral administration
AUC0-∞ (µg h/mL) 9.76 ± 1.65 3.51 ± 0.19 4.17 ± 0.05 7.13 ± 0.44 0.89 ± 0.02
Cmax (µg/mL) 8.97 ± 0.79 1.07 ± 0.07 1.06 ± 0.03 0.65 ± 0.04 0.38 ± 0.01
Tmax (h) 0.67 ± 0.11 0.67 ± 0.11 0.50 ± 0.01 0.58 ± 0.08 0.50 ± 0.01
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Materials and Methods
Chemicals and reagents
Deionized water was prepared using a Maxima ultra-pure water pu-
rifier system purchased from Elga. HPLC grade methanol and ace-
tonitrile were purchased from Merck. Sephadex LH-20 (No. 17–
0090–02) was purchased from GE Healthcare. Sodium heparin was 
purchased from Acros Organic. Acetic acid was purchased from 
Systerm ChemAR.
Isolation of bioactive compounds
Frog Fruit [L. nodiflora (L.) Michx.] plants were collected from Ser-
emban, Negeri Sembilan, Malaysia. The plant was authenticated 
by Dr. Rahmad Zakaria, a botanist of the Herbarium Unit, School of 
Biological Sciences, University of Science Malaysia (Universiti Sains 
Malaysia). A voucher specimen (No. 11594) was deposited at the 
same unit. The 5 antihyperuricemic constituents, namely, arenar-
ioside (1), verbascoside (2), 6-hydroxyluteolin (3), 6-hydroxylute-
olin-7-O-glycoside (4), and nodifloretin (5) (▶Fig. 4), were isolat-
ed from the bioactive fraction of L. nodiflora following the protocol 
described previously [19] and were used as marker compounds for 
the method validation and quantification of rat plasma samples. 
The purity of the compounds was determined using an Agilent 
1120 Compact LC system equipped with a variable wavelength pho-
tometric detector and Agilent EZ-Chrom Elite Compact Software 
(Agilent Technologies) [24]. The purities were found to be 97.71, 
98.19, 96.25, 97.30, and 97.36 % for 1, 2, 3, 4, and 5, respectively.
Instrumentation
The HPLC system consisted of an Agilent 1120 Compact LC system 
equipped with a variable wavelength photometric detector set at 
a wavelength of 340 nm, and Agilent EZ-Chrom Elite Compact Soft-
ware (Agilent Technologies). An Inertsil ODS-3 (4.6 mm 
i.d. × 250 mm, GL Ssciences Inc.) column pre-connected with an In-
ertsil ODS-3 guard column (4.6 mm i.d. × 50 mm, GL Sciences Ins.) 
was used for the chromatographic separation. The mobile phase 
consisting of 0.1 % aqueous acetic acid (A) and acetonitrile (B) was 
delivered with gradient elution at a flow rate of 1.0 mL/min at room 
temperature. The gradient elution was programmed as follows: 
0–25 min, 15 % B; 25–30 min, 20 % B; 30–35 min, 36 % B; 35–38 min, 
15 % B. This was followed by a 12-min equilibration period prior to 
the injection of each sample [24].
Sample preparation
Frozen plasma samples were thawed at the room temperature. A 
plasma sample (100 µL) was transferred into a 1.5-mL microcentri-
fuge tube and proteins were precipitated by adding 100 µL of meth-
anol. The mixture was vortexed for 1 min using an Autovortex SA6 
(Stuart Scientific) and then centrifuged at 7711 × g using a Micro 
12 centrifuge (Hanil Science Industrial) for 15 min. The supernatant 
was transferred into a new microcentrifuge tube and 20 µL were 
used for injection.
Limit of detection, limit of quantification, and 
linearity
The calibration curves were constructed by plotting peak areas 
against the concentrations of the analyte prepared at 312.5, 625, 
2 500, 5 000, 10 000, and 20 000 ng/mL for 3 and 156.3, 625, 2 500, 
5 000, 10 000, and 20 000 ng/mL for 1, 2, 4 and 5. The linearity of 
the curves was evaluated by linear regression analysis and was ex-
pressed as the r2. LOD and LOQ were determined by triplicate anal-
ysis of a series of successive twofold dilutions of the stock solutions. 
The LOD was defined as the lowest concentration that the analyti-
cal system can reliably differentiate from the background level and 
was calculated based on a signal-to-noise ratio of 3:1. The LOQ was 
defined as the lowest quantifiable concentration on the calibration 
curve and was calculated based on a signal-to-noise ratio of 12:1 
[24, 31, 32].
Method validation
The method was validated through intraday and inter-day analysis 
of precision and accuracy according to the International Confer-
ence on Harmonisation guidelines [33]. The intraday accuracy and 
precision were determined for each compound by evaluating six 
replicate measurements of each concentration on a single day, 
while the inter-day accuracy and precision were determined by as-
sessing measurements of each concentration over 6 consecutive 
days [24]. The recovery of the direct extraction method using 
methanol was calculated by comparing the peak area of the com-
pounds after extraction with those of the compounds dissolved in 
the methanol at a similar concentration [24]. Accuracy was ex-
pressed as a percentage of true value, while precision was ex-
pressed as a CV [24].
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Animals
Male Sprague-Dawley rats (260–300 g) were obtained from the 
Animal Research and Service Centre of the University of Science 
Malaysia (Universiti Sains Malaysia) and were kept in the animal 
transit room of the School of Pharmaceutical Sciences, University 
of Science Malaysia (Universiti Sains Malaysia), Penang, Malaysia. 
They were maintained on a 12-h light/dark cycle at a room tem-
perature of 25°C and were allowed free access to standard food pel-
lets and tap water. The animals were acclimatized for 1 week prior 
to experimentation. The study protocol was approved by the Ani-
mal Ethics Committee, University of Science Malaysia (Universiti 
Sains Malaysia), Penang, Malaysia [USM/Animal Ethics Approv-
al/2013/(89)(478)] and was in accordance with institutional guide-
lines (Guideline for the Care and Used of Animals for Scientific Pur-
poses, USM) and international policies (Public Health Service 
Policy on Humane Care and Use of Laboratory Animal, and Guide 
for the Care and Use of Laboratory Animals) [34, 35].
Pharmacokinetic study
The animals were divided into two groups of three each and the 
study was conducted according to a two-way crossover study de-
sign. Food, but not water, was withheld overnight prior to the ex-
perimentation. Group 1 (n = 3) was intravenously injected with a 
mixture comprising bioactive compounds 1–5 (2 mg/kg of each 
compound), while group 2 (n = 3) was orally administered with a 
mixture consisting of bioactive compounds 1–5 (20 mg/kg of each 
compound). After a washout period of 2 weeks, the animals from 
group 1 were orally administered with a mixture of 1–5 compris-
ing 20 mg/kg each of 1–5, while those from group 2 were intrave-
nously injected with another mixture of 1–5 consisting of 2 mg/kg 
each of 1–5. For both routes of drug administration, the mixture of 
1–5 was prepared in 20 % of Tween 20 aqueous solution. The vol-
ume for intravenous injection and oral administration was 1 mL/kg 
and 5 mL/kg of body weight, respectively. The animals were placed 
in animal restraining cage during blood collection and the blood 
samples of 0.5 mL were collected by the tail nipping method into 
a sodium heparin-coated microcentrifuge tube at 0, 0.5, 1, 1.5, 2, 
2.5, 3, 3.5, 4, 6, 8, 10, and 24 h after drug administration. The blood 
samples were centrifuged at 4 000 × g for 15 min and the resulting 
plasma samples were kept frozen at  − 20°C prior to analysis [31].
Data analysis
The following pharmacokinetic parameters were calculated: The 
elimination rate constant (Ke) was calculated from the slope of plas-
ma concentration versus time curve. The slope of the curve was 
equal to Ke/2.303. The elimination half-life (t1/2) was determined 
as 0.693/Ke, while the volume of distribution (Vd) was estimated 
using the equation Vd = dose/Ke × AUC0−∞. The theoretical concen-
tration at time zero (Co) was calculated as the intercept of the sem-
ilogarithmic concentration-time curve. The area under the plasma 
concentration-time curve to infinity (AUC0−∞) was determined 
by combining the area from time zero to the last sampling time 
(AUC0−t) with the area from the last sampling time to infinity 
(AUCt−∞), whereby the trapezoidal rule was applied. Total body 
clearance (CL) was estimated from the relationship CL = dose/
AUC0−∞. Peak concentration (Cmax) and time to reach Cmax (Tmax) 
following oral administration were obtained directly from the plas-
ma concentration-time plots. The absolute oral bioavailability (F) 
was calculated as the ratio of the dose-normalized AUC (AUC/dose) 
after oral and intravenous administration. The results are expressed 
as the mean ± SEM.
Supporting Information
The 1H- and 13C-NMR, MS, UV, and IR data of 1–5 are available as 
Supporting Information.
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